Custom Criteria for
BlueCross Blue Shield of Rhode Island Commercial

catamaran™

XTANDI® (enzalutamide)

GPI CODING:

21402430000120

DESCRIPTION:

Xtandi is indicated for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel. Xtandi is an androgen receptor inhibitor that acts on multiple steps in the androgen receptor signaling pathway. Xtandi competitively inhibits androgen binding to androgen receptors and inhibits androgen receptor nuclear translocation and interaction with DNA.

APPROVAL DURATION:

Approval duration: 24 months

CRITERIA FOR XTANDI:

I. Patient has a diagnosis of metastatic castration-resistant prostate cancer **AND**
II. Patient has previously received docetaxel

OR

III. Off label uses for oncology drugs are approvable if considered medically acceptable in one or more of the following compendia (i.e., Micromedex DrugDex, AHFS, Clinical Pharmacology, and NCCN.)) *A use is identified by a compendium as medically accepted if the:*
   - *Indication is a Category 1 or 2A in NCCN,*
   - *Indication is a Class I, Class IIa or Class IIb in DrugDex,*
   - *Narrative text in AHFS or Clinical Pharmacology is supportive; or*
   - *The use is supported by clinical research in 2 or more peer-reviewed medical journals as specified in the Compendial SOP document.*